Gut Barrier Study in Ulcerative Colitis Remission
Part of Digestive system clinical trials.
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with ulcerative colitis for at least 6 months.
- Your ulcerative colitis is currently in remission (no symptoms) and a stool test shows low inflammation levels.
- You are willing to have a liver stiffness test (FibroScan) done.
- You do not have other liver disease, heavy alcohol use, or other conditions listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to monitor ulcerative colitis using stool tests and colonoscopy to detect early signs of cancer. It may help doctors manage long-term ulcerative colitis more safely.
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
This study uses breath tests to see how a special diet changes gases in your gut that might affect ulcerative colitis. It aims to find out if these changes can help manage your condition.
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
This study tests whether monitoring ulcerative colitis with stool-based markers—simple, non-invasive tests—can help guide treatment as effectively as the usual care approach. It aims to see if this strategy helps you stay in remission and avoid flare-ups.
This study tests an experimental drug called HSK47388 for people with moderate to severe ulcerative colitis who have not had good results from other treatments. The goal is to see if it can reduce inflammation and improve symptoms.
Hear when a new Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.